Immunotherapy for fungal infections

Current Opinion in Microbiology

Volumn 15, Issue 4, 2012, Pages 434-439

  Armstrong James, Darius ^a   Harrison, Thomas S ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; IMMUNOMODULATING AGENT; RECOMBINANT GAMMA INTERFERON;

ADOPTIVE IMMUNOTHERAPY; CHRONIC GRANULOMATOUS DISEASE; FUNGUS IMMUNITY; GENE THERAPY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; REVIEW; SYSTEMIC MYCOSIS; T LYMPHOCYTE;

ANTIFUNGAL AGENTS; GENETIC THERAPY; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MYCOSES; T-LYMPHOCYTES;

EID: 84865301055     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2012.06.001     Document Type: Review

References (51)

1. Warnock D.W. Trends in the epidemiology of invasive fungal infections. Nihon Ishinkin Gakkai Zasshi 2007, 48:1-12.
2. Segal B.H., Steinbach W.J. Combination antifungals: an update. Expert Rev Anti Infect Ther 2007, 5:883-892.
3. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
4. Morris A., Lundgren J.D., Masur H., Walzer P.D., Hanson D.L., Frederick T., Huang L., Beard C.B., Kaplan J.E. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004, 10:1713-1720.
5. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., Ito J., Andes D.R., Baddley J.W., Brown J.M., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010, 50:1091-1100.
6. Pappas P.G., Alexander B.D., Andes D.R., Hadley S., Kauffman C.A., Freifeld A., Anaissie E.J., Brumble L.M., Herwaldt L., Ito J., et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010, 50:1101-1111.
7. Kriengkauykiat J., Ito J.I., Dadwal S.S. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol 2011, 3:175-191.
8. Howard S.J., Cerar D., Anderson M.J., Albarrag A., Fisher M.C., Pasqualotto A.C., Laverdiere M., Arendrup M.C., Perlin D.S., Denning D.W. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009, 15:1068-1076.
9. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011, 11:275-288.
10. Armstrong-James D.P., Turnbull S.A., Teo I., Stark J., Rogers N.J., Rogers T.R., Bignell E., Haynes K. Impaired interferon-gamma responses, increased interleukin-17 expression, and a tumor necrosis factor-alpha transcriptional program in invasive aspergillosis. J Infect Dis 2009, 200:1341-1351.
11. Cenci E., Mencacci A., Del Sero G., Bacci A., Montagnoli C., d'Ostiani C.F., Mosci P., Bachmann M., Bistoni F., Kopf M., et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999, 180:1957-1968.
12. Park S.J., Hughes M.A., Burdick M., Strieter R.M., Mehrad B. Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis. J Immunol 2009, 182:4306-4312.
13. de Boer M.G., Jolink H., Halkes C.J., van der Heiden P.L., Kremer D., Falkenburg J.H., van de Vosse E., van Dissel J.T. Influence of polymorphisms in innate immunity genes on susceptibility to invasive aspergillosis after stem cell transplantation. PLoS ONE 2011, 6:e18403.
14. Armstrong-James D., Teo I.A., Shrivastava S., Petrou M.A., Taube D., Dorling A., Shaunak S. Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant 2010, 10:1796-1803.
15. Halloran P.F., Afrouzian M., Ramassar V., Urmson J., Zhu L.F., Helms L.M., Solez K., Kneteman N.M. Interferon-gamma acts directly on rejecting renal allografts to prevent graft necrosis. Am J Pathol 2001, 158:215-226.
16. Safdar A., Rodriguez G., Ohmagari N., Kontoyiannis D.P., Rolston K.V., Raad I.I., Champlin R.E. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005, 103:731-739.
17. Bodasing N., Seaton R.A., Shankland G.S., Pithie A. Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient. J Antimicrob Chemother 2002, 50:765-766.
18. Longley N., Muzoora C., Taseera K., Mwesigye J., Rwebembera J., Chakera A., Wall E., Andia I., Jaffar S., Harrison T.S. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008, 47:1556-1561.
19. Jarvis J.N., Meintjes G., Rebe K., Williams G.N., Bicanic T., Williams A., Schutz C., Bekker L.G., Wood R., Harrison T.S. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012, 26:1105-1113.
20. Pappas P.G., Bustamante B., Ticona E., Hamill R.J., Johnson P.C., Reboli A., Aberg J., Hasbun R., Hsu H.H. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004, 189:2185-2191.
21. Jarvis J.N.C.J., Stone H., Meintjes G., Harrison T.S., Koup R.A. The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. CROI: 2012 2012, 956.
22. Pirofski L.A., Casadevall A. The damage-response framework of microbial pathogenesis and infectious diseases. Adv Exp Med Biol 2008, 635:135-146.
23. Larsen R.A., Pappas P.G., Perfect J., Aberg J.A., Casadevall A., Cloud G.A., James R., Filler S., Dismukes W.E. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 2005, 49:952-958.
24. Dadachova E., Nakouzi A., Bryan R.A., Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA 2003, 100:10942-10947.
25. Bryan R.A., Jiang Z., Howell R.C., Morgenstern A., Bruchertseifer F., Casadevall A., Dadachova E. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J Infect Dis 2010, 202:633-637.
26. Pachl J., Svoboda P., Jacobs F., Vandewoude K., van der Hoven B., Spronk P., Masterson G., Malbrain M., Aoun M., Garbino J., et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006, 42:1404-1413.
27. Cowen L.E., Singh S.D., Kohler J.R., Collins C., Zaas A.K., Schell W.A., Aziz H., Mylonakis E., Perfect J.R., Whitesell L., et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 2009, 106:2818-2823.
28. Louie A., Stein D.S., Zack J.Z., Liu W., Conde H., Fregeau C., Vanscoy B.D., Drusano G.L. Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis. Antimicrob Agents Chemother 2011, 55:3295-3304.
29. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812.
30. Goodman A.R., Cardozo T., Abagyan R., Altmeyer A., Wisniewski H.G., Vilcek J. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev 1996, 7:191-202.
31. Garlanda C., Hirsch E., Bozza S., Salustri A., De Acetis M., Nota R., Maccagno A., Riva F., Bottazzi B., Peri G., et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002, 420:182-186.
32. Gaziano R., Bozza S., Bellocchio S., Perruccio K., Montagnoli C., Pitzurra L., Salvatori G., De Santis R., Carminati P., Mantovani A., et al. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother 2004, 48:4414-4421.
33. D'Angelo C., De Luca A., Zelante T., Bonifazi P., Moretti S., Giovannini G., Iannitti R.G., Zagarella S., Bozza S., Campo S., et al. Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunol 2009, 183:4609-4618.
34. You J., Zhuang L., Cheng H.Y., Yan S.M., Yu L., Huang J.H., Tang B.Z., Huang M.L., Ma Y.L., Chongsuvivatwong V., et al. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol 2006, 12:6715-6721.
35. Romani L., Bistoni F., Gaziano R., Bozza S., Montagnoli C., Perruccio K., Pitzurra L., Bellocchio S., Velardi A., Rasi G., et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004, 103:4232-4239.
36. Romani L., Bistoni F., Perruccio K., Montagnoli C., Gaziano R., Bozza S., Bonifazi P., Bistoni G., Rasi G., Velardi A., et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 2006, 108:2265-2274.
37. Rauser G., Einsele H., Sinzger C., Wernet D., Kuntz G., Assenmacher M., Campbell J.D., Topp M.S. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004, 103:3565-3572.
38. Perruccio K., Tosti A., Burchielli E., Topini F., Ruggeri L., Carotti A., Capanni M., Urbani E., Mancusi A., Aversa F., et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005, 106:4397-4406.
39. Stuehler C., Khanna N., Bozza S., Zelante T., Moretti S., Kruhm M., Lurati S., Conrad B., Worschech E., Stevanovic S., et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 2011, 117:5881-5891.
40. Liu M., Clemons K.V., Bigos M., Medovarska I., Brummer E., Stevens D.A. Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine 2011, 29:1745-1753.
41. Khanna N., Stuehler C., Conrad B., Lurati S., Krappmann S., Einsele H., Berges C., Topp M.S. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 2011, 118:1121-1131.
42. Bozza S., Perruccio K., Montagnoli C., Gaziano R., Bellocchio S., Burchielli E., Nkwanyuo G., Pitzurra L., Velardi A., Romani L. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003, 102:3807-3814.
43. Montagnoli C., Perruccio K., Bozza S., Bonifazi P., Zelante T., De Luca A., Moretti S., D'Angelo C., Bistoni F., Martelli M., et al. Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation. Blood Cells Mol Dis 2008, 40:55-62.
44. Ang A.L., Linn Y.C. Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era--experience from an adult haematology unit in Singapore. Transfus Med 2011, 21:13-24.
45. Safdar A., Hanna H.A., Boktour M., Kontoyiannis D.P., Hachem R., Lichtiger B., Freireich E.J., Raad I.I. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004, 101:2859-2865.
46. Lin L., Ibrahim A.S., Baquir B., Fu Y., Applebaum D., Schwartz J., Wang A., Avanesian V., Spellberg B. Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. J Infect Dis 2010, 201:1708-1717.
47. Segal B.H., Veys P., Malech H., Cowan M.J. Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant 2011, 17(1 Suppl.):S123-S131.
48. Rahman F.Z., Hayee B., Chee R., Segal A.W., Smith A.M. Impaired macrophage function following bacterial stimulation in chronic granulomatous disease. Immunology 2009, 128:253-259.
49. Segal B.H., Romani L.R. Invasive aspergillosis in chronic granulomatous disease. Med Mycol 2009, 47(Suppl. 1):S282-S290.
50. Bianchi M., Niemiec M.J., Siler U., Urban C.F., Reichenbach J. Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J Allergy Clin Immunol 2011, 127:1243-1252. e1247.
51. Bruns S., Kniemeyer O., Hasenberg M., Aimanianda V., Nietzsche S., Thywissen A., Jeron A., Latge J.P., Brakhage A.A., Gunzer M. Production of extracellular traps against Aspergillus fumigatus in vitro and in infected lung tissue is dependent on invading neutrophils and influenced by hydrophobin RodA. PLoS Pathog 2010, 6:e1000873.